Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above [Phase 1]

View source ↗

Summary

This clinical trial update summarizes a Phase 1 study assessing the safety and immunogenicity of the IN006 RSV vaccine in healthy adults aged 18 years and older…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• IN006

Snippet

Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: ACTIVE_NOT_RECRUITING